Al Amir, H., Orabi, O., Nour El Din, A. (2019). Functional Dyspepsia….An Update. test, 23(2), 189-196. doi: 10.21608/smj.2019.47713
Haitham Mohammad Al Amir; Osama Abbas Orabi; Ahmed Nagah Nour El Din. "Functional Dyspepsia….An Update". test, 23, 2, 2019, 189-196. doi: 10.21608/smj.2019.47713
Al Amir, H., Orabi, O., Nour El Din, A. (2019). 'Functional Dyspepsia….An Update', test, 23(2), pp. 189-196. doi: 10.21608/smj.2019.47713
Al Amir, H., Orabi, O., Nour El Din, A. Functional Dyspepsia….An Update. test, 2019; 23(2): 189-196. doi: 10.21608/smj.2019.47713

Functional Dyspepsia….An Update

Sohag Medical Journal
Article 36, Volume 23, Issue 2, April 2019, Pages 189-196    PDF (385.38 K)
Document Type: Original Article
DOI: 10.21608/smj.2019.47713
Authors
Haitham Mohammad Al Amir1; Osama Abbas Orabi2; Ahmed Nagah Nour El Din1
1Department of Internal medicine, Faculty of Medicine, Sohag university.
2Department of Internal Medicine, Faculty of Medicine, Sohag University Hospital.
Supplementary Files
References
  1. Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med 2015; 373:1853.
  2. Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015; 64: 1049 – 57.
  3. Ford AC, Forman D, Bailey AG et al. Effect of dyspepsia on survival: a longitudinal 10-year follow up study. Am J Gastroenterol 2012; 107: 912 – 21.
  4. Ford AC, Forman D, Bailey AG et al. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2007; 56: 321 – 7.
  5. Veldhuyzen van Zanten S, Wahlqvist P, Talley NJ et al. Randomized
 

clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole—results from the STARS II study. Aliment Pharmacol Ther 2011; 34: 714 – 23.

  1. Lacy BE, Weiser KT, Kennedy AT et al. Functional dyspepsia: the economic impact on patients. Aliment Pharmacol Ther 2013; 38: 170– 7.
  2. Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001; 134:815.
  3. Koch KL, Stern RM. Functional disorders of the stomach. Semin Gastrointest Dis 1996; 7:185.
  4. Malagelada JR. Functional dyspepsia. Insights on mechanisms and management strategies. Gastroenterol Clin North Am 1996; 25:103.
  5.  Stanghellini V, Chan FKL, Hasler WL et al. Gastroduodenal disorders. Gastroenterology 2016; 150: 1380- 92.
  6. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders .Gastroenterology 2006; 130: 1466- 79.
  7. Vakil N, Halling K, Ohlsson L et al. Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol 2013; 108: 767- 74.
  8.  Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Am J Gastroenterol 2017; 112:132.
  9. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115:1346.
  10.  Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276.
  11.  Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130:296.
  12.  Scolapio JS, Camilleri M. Non-ulcer dyspepsia. Gastroenterologist 1996; 4:13.
  13.  Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43:2028.
  14.  Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and post-meal symptoms in functional dyspepsia. Gastroenterology 2004; 127:1685.
  15.  Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101:999.
  16.  Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42:814.
  17.  Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116:515.
  18.  Camilleri M, Malagelada JR, Kao PC, Zinsmeister AR. Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986; 31:1169.
  19.  Iovino P, Azpiroz F, Domingo E, Malagelada JR. The sympathetic nervous system modulates perception and reflex responses to gut distention in humans. Gastroenterology 1995; 108:680.
  20.  Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: an H(2)(15)O-PET study. Am J Gastroenterol 2010; 105: 913.
  21.  Aziz Q, Fass R, Gyawali CP, et al.: Functional Esophageal Disorders. Gastroenterology. 2016; 105(6): 1368–1379. PII: S0016-5085(16)00178-5.
  22.  Quigley EM, Lacy BE: Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol. 2013; 10(3): 175–86.
  23.  Piessevaux H, De Winter B, Louis E, et al.: Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neuro Gastroenterol Motil. 2009; 21(4): 378–88.
  24.  Choung RS, Locke GR 3rd, Schleck CD, et al.: Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil. 2012; 24(3): 229–34, e106.
  25.  Mearin F, Lacy BE, Chang L, et al.: Bowel Disorders. Gastroenterology. 2016; 150(6): 1393–1407.e5. PII: S0016-5085(16)00222-5.
  26.  Wang A, Liao X, Xiong L, et al.: The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008; 8: 43.
  27.  Futagami S, Yamawaki H, Shimpuku M, et al.: Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia. J Nippon Med Sch. 2013; 80(5): 362–70.
  28.  Piacentino D, Cantarini R, Alfonsi M, et al.: Psychopathological features of irritable bowel syndrome patients with and without functional dyspepsia: a cross-sectional study. BMC Gastroenterol. 2011; 11: 94.
  29.  Ford AC, Marwaha A, Lim A, et al.: Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010; 8(5): 401- 9.
  30.  Vanheel H, Vicario M, Vanuytsel T, et al.: Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014; 63(2): 262–71.
  31.  Talley NJ: Functional Dyspepsia: Advances in Diagnosis and Therapy. Gut Liver. 2017; 11(3): 349–57.
  32.  Pinto-Sanchez MI, Yuan Y, Bercik P, et al.: Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017; 3: CD011194.
  33.  Coyle C, Crawford G, Wilkinson J, et al.: Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther. 2017; 45(12): 1524–33.
  34.  Thomas E, Wade A, Crawford G, et al.: Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2014; 39(6): 595–602.
  35. Matsushita M, Masaoka T, Suzuki H: Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia. Neurogastroenterol Motil. 2016; 28(5): 631–8. PubMed Abstract | Publisher Full Text | F1000 Recommendation
  36. 29.  Nakamura K, Tomita T, Oshima T, et al.: A double-blind placebo-controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017; 52(5): 602–10. PubMed Abstract | Publisher Full Text
  37.  Matsueda K, Hongo M, Tack J, et al.: A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012; 61(6): 821–8.
  38.  Kessing BF, Smout AJ, Bennink RJ, et al.: Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neuro Gastroenterol Motil. 2014; 26(8): 1079–86.
  39.  Carbone F, Rotondo A, Andrews CN, et al.: 1077 A Controlled Cross-Over Trial Shows Benefit of Prucalopride for Symptom Control and Gastric Emptying Enhancement in Idiopathic Gastroparesis. Gastroenterology. 2016; 150(4, supplement 1): S213–S214.
  40.  Sáez-González E, Conde I, Díaz-Jaime FC, et al.: Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation. Am J Gastroenterol. 2016; 111(9): 1364–5.
  41.  Suzuki H, Matsuzaki J, Fukushima Y, et al.: Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014; 26(7): 950–61.
  42.  Ford AC, Luthra P, Tack J, et al.: Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017; 66(3): 411–20.
  43.  Talley NJ, Locke GR, Saito YA, et al.: Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015; 149(2): 340–9.e2.
  44.  Soo S, Moayyedi P, Deeks J, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005; 2: CD002301.
  45.  Pang B, Jiang T, Du YH, et al.: Acupuncture for Functional Dyspepsia: What Strength Does It Have? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2016; 2016: 3862916.
  46.  ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol, 20 June 2017; DOI: 10.1038/ajg.2017.154
 

Statistics
Article View: 222
PDF Download: 481